natgillin/translations-raw huggingface dataset:
Symptoms have included tremor, headache, nausea and vomiting, infections, urticaria, lethargy and increases in blood urea nitrogen, serum creatinine and alanine aminotransferase levels. 
urtikariju, letargiju i povišene razine dušika iz ureje u krvi, kreatinina u serumu i alanin aminotransferaze.
Nervous system disorders headache, tremor nervous system disorders seizures, disturbances in consciousness, peripheral neuropathies, dizziness, paraesthesias and dysaesthesias, writing impaired encephalopathy, central nervous system haemorrhages and cerebrovascular accidents, coma, speech and language ab-normalities, paralysis and paresis, amnesia hypertonia myasthenia 
Poremećaji živčanog sustava glavobolja, tremor epizode poremećaja živčanog sustava, poremećaji svijesti, periferne neuropatije, omaglica, parestezije i dizestezije, narušena sposobnost pisanja encefalopatija, krvarenja u središnjem živčanom sustavu i cerebrovaskularni incidenti, koma,
Do not drive or use any tools or machines if you feel dizzy or sleepy, or have problems seeing clearly after taking Envarsus. 
Ako nakon uzimanja Envarsusa imate omaglicu, osjećate pospanost ili Vam je zamućen vid, nemojte voziti, koristiti alate ili upravljati strojevima.
Rare side effects (may affect up to 1 in 1,000 people): - Small bleedings in your skin due to blood clots - Increased muscle stiffness - Blindness, deafness 
Rijetke nuspojave (mogu se pojaviti u do 1 na 1000 osoba): - sitna krvarenja u koži zbog krvnih ugrušaka
Chiesi España, S.A.U. 
Chiesi S.A.S.
Envarsus 0.75 mg prolonged-release tablets are oval, white to off-white uncoated tablet, debossed with “0.75” on one side and “TCS” on the other side. 
Envarsus 0,75 mg tablete s produljenim oslobađanjem su ovalne, bijele do bjelkaste neobložene tablete, s utisnutom oznakom „0.75“ na jednoj strani i „TCS“ na drugoj strani.
Human data show that tacrolimus crosses the placenta. 
Podaci iz ispitivanja provedenih u ljudi pokazuju da takrolimus prolazi kroz posteljicu.
Skin and subcutaneous tissue disorders rash, pruritus, alopecias, acne, sweating increased dermatitis, photosensitivity toxic epidermal necrolysis (Lyell's syndrome) 
pojačano znojenje dermatitis, fotoosenzitiv nost toksična epidermalna nekroliza (Lyellov sindrom)
Inadvertent, unintentional, or unsupervised switching of immediate- or prolonged-release formulations of tacrolimus is unsafe. 
Nepažljivo, nenamjerno ili nenadzirano mijenjanje farmaceutskih oblika takrolimusa s trenutnim oslobađanjem s farmaceutskim oblikom takrolimusa s produljenim oslobađanjem nije sigurno.
Musculoskeletal and connective tissue disorders arthralgia, back pain, muscle cramps, pain in limb joint disorders mobility decreased 
Poremećaji mišićno koštanog sustava i vezivnog tkiva artralgija, bol u leđima, grčevi u mišićima, bol u udovima poremećaji zglobova smanjena pokretljivost
Allograft transplant patients maintained on twice daily Prograf (immediate-release) or Advagraf (once daily) dosing requiring conversion to once daily Envarsus should be converted on a 1:0.7 (mg:mg) 
U bolesnika s alogenim presatkom koji uzimaju Prograf (s trenutnim oslobađanjem) dva puta na dan ili Advagraf (jedanput na dan), a moraju prijeći na Envarsus koji se uzima jedanput na dan, prelazak treba biti u omjeru ukupne dnevne doze 1: 0,7 (mg:mg), stoga doza održavanja Envarsusa treba biti 30% manja od doze Prografa ili Advagrafa.
The kidneys and the pancreas were the primary organs affected in toxicity studies performed in rats and baboons. 
U ispitivanjima toksičnosti koja su provedena u štakora i babuna, primarno su bili zahvaćeni bubrezi i gušterača.
Medication errors, including inadvertent, unintentional or unsupervised substitution of immediate- or prolonged-release tacrolimus formulations, have been observed. 
Primijećene su medikacijske pogreške, uključujući nepažljivo, nenamjerno ili nenadzirano mijenjanje farmaceutskih oblika takrolimusa s trenutnim oslobađanjem s onima s produljenim oslobađanjem.
Oval, white to off-white uncoated tablet, debossed with “0.75” on one side and “TCS” on the other side. 
Ovalna, bijela do bjelkasta neobložena tableta, s utisnutom oznakom „0.75“ na jednoj strani i „TCS“ na drugoj strani.
Metabolism and nutrition disorders diabetes mellitus, hyperglycaemic conditions, hyperkalaemia anorexia, metabolic acidoses, other electrolyte abnormalities, hyponatraemia, fluid overload, hyperuricaemia, hypomagnesaemia, hypokalaemia, hypocalcemia, appetite decreased, hypercholesterolaemia, hyperlipidaemia, hypertriglyceridaemia, hypophosphateaemia dehydration, hypoglycaemia, hypoproteinaemia, hyperphosphataemia 
hiperuricemija, hipomagnezijemija, hipokalijemija, hipokalcijemija smanjen tek, hiperkolesterolemija, hiperlipidemija, hipertrigliceridemija, hipofosfatemija dehidracija, hipoglikemija, hipoproteinemija, hiperfosfatemija
CYP3A4 inhibitors potentially leading to increased tacrolimus blood levels Clinically, the following substances have been shown to increase tacrolimus blood levels: Strong interactions have been observed with antifungal agents such as ketoconazole, fluconazole, itraconazole, voriconazole and isavuconazole, the macrolide antibiotic erythromycin, HIV protease inhibitors (e.g. ritonavir, nelfinavir, saquinavir) or Hepatitis C Virus (HCV) protease inhibitors (e.g. telaprevir, boceprevir, and the combination of ombitasvir and paritaprevir with ritonavir, when used with and without dasabuvir), the pharmacokinetic enhancer cobicistat, and the tyrosine kinase inhibitors nilotinib and imatinib. 
Opažene su jake interakcije s antimikoticima poput ketokonazola, flukonazola, itrakonazola, vorikonazola i izavukonazola, s makrolidnim antibiotikom eritromicinom, inhibitorima proteaze HIV-a (npr. ritonavirom, nelfinavirom, sakvinavirom), inhibitorima proteaze HCV-a (npr. telaprevirom, boceprevirom i kombinacijom ombitasvira i paritaprevira s ritonavirom, primijenjenom s dasabuvirom ili bez njega), farmakokinetičkim pojačivačem kobicistatom te inhibitorima tirozin-kinaze nilotinibom i imatinibom.
Talk to your doctor before taking Envarsus: - if you have, or have had, liver problems. 
Obratite se svom liječniku prije nego uzmete Envarsus: - ako imate ili ste imali problema s jetrom - ako imate proljev koji traje dulje od jednog dana - ako uzimate bilo koji od lijekova navedenih pod „Drugi lijekovi i Envarsus“ - ako imate poremećaj električne aktivnosti srca koji se zove „produljenje QT-intervala“.
Envarsus 0.75 mg prolonged-release tablets Envarsus 1 mg prolonged-release tablets Envarsus 4 mg prolonged-release tablets 
Envarsus 0,75 mg tablete s produljenim oslobađanjem Envarsus 1 mg tablete s produljenim oslobađanjem Envarsus 4 mg tablete s produljenim oslobađanjem
Prophylaxis of liver transplant rejection 
Sprječavanje odbacivanja presatka jetre
Eye disorders, sometimes progressing to loss of vision, have been reported in patients treated with tacrolimus. 
U bolesnika liječenih takrolimusom prijavljeni su poremećaji oka, koji su ponekad uznapredovali do gubitka vida.
Hepatobiliary disorders bile duct disorders, hepatocellular damage and hepatitis, cholestasis and jaundice venoocclusive liver disease, hepatic artery thrombosis hepatic failure 
hepatocelularno oštećenje i hepatitis, kolestaza i žutica venookluzivna bolest jetre, tromboza arterije jetre zatajenje jetre
The event rate of biopsy-confirmed acute rejection within the 360-day study period was not significantly different between the Envarsus group and the tacrolimus immediate-release group. 
Stopa akutne reakcije odbacivanja presatka potvrđena biopsijom tijekom 360 dana ispitivanja nije se značajno razlikovala između skupine liječene
These may worsen kidney or nervous system problems when taken together with Envarsus. 
Ako se uzmu zajedno s Envarsusom, ti lijekovi mogu pogoršati probleme s bubrezima ili živčanim sustavom.
All patients reported risk factors for PRCA such as parvovirus B19 infection, underlying disease or concomitant medicinal product associated with PRCA. 
kao što je infekcija parvovirusom B19, podležeća bolest ili istodobno uzimanje lijekova koji su povezani s nastankom PRCA.
Investigations liver function tests abnormal blood alkaline phosphatase increased, weight increased amylase increased, ECG abnormal, heart rate and pulse investigations abnormal, weight decreased, blood lactate dehydrogenase increased echocardiogram abnormal, 
Pretrage poremećeni nalazi testova jetrene funkcije povišena razina alkalne fosfataze u krvi, povećanje tjelesne težine povišena razina amilaze,
- if you are allergic to sirolimus or to any macrolide-antibiotic (e.g. erythromycin, clarithromycin, josamycin). 
- ako ste alergični na takrolimus ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.). - ako ste alergični na sirolimus ili neki makrolidni antibiotik (npr. eritromicin,
Oval, white to off-white uncoated tablet, debossed with “1” on one side and “TCS” on the other side. 
Ovalna, bijela do bjelkasta neobložena tableta, s utisnutom oznakom „1“ na jednoj strani i „TCS“ na drugoj strani.
In isolated patients with very high plasma levels, haemofiltration or -diafiltration have been effective in reducing toxic concentrations. 
Hemofiltracija ili hemodijafiltarcija bile su učinkovite u smanjivanju toksičnih koncentracija u izoliranim slučajevima bolesnika s vrlo visokom razinom u plazmi.
If patients taking tacrolimus present with symptoms indicating PRES such as headache, altered mental status, seizures and visual disturbances, a radiological procedure (e.g. MRI) should be performed. 
Ako se u bolesnika koji uzimaju takrolimus pojave simptomi koji ukazuju na PRES, kao što su glavobolja,
Based on its high molecular weight, poor aqueous solubility, and extensive erythrocyte and plasma protein binding, it is anticipated that tacrolimus will not be dialysable. 
Pretpostavlja se da se takrolimus ne može ukloniti dijalizom zbog svoje visoke molekularne težine, slabe topljivosti u vodi i vezanja u velikoj mjeri za eritrocite i proteine plazme.
Envarsus 0.75 mg prolonged-release tablets tacrolimus 
Envarsus 0,75 mg tablete s produljenim oslobađanjem tacrolimus
Envarsus 1 mg prolonged-release tablets are oval, white to off-white uncoated tablet, debossed with “1” on one side and “TCS” on the other side 
Envarsus 1 mg tablete s produljenim oslobađanjem su ovalne, bijele do bjelkaste neobložene tablete, s utisnutom oznakom „1“ na jednoj strani i „TCS“ na drugoj strani.
Envarsus 0.75 mg prolonged-release tablets 
Envarsus 0,75 mg tablete s produljenim oslobađanjem
Envarsus 4 mg prolonged-release tablets are oval, white to off-white uncoated tablet, debossed with “4” on one side and “TCS” on the other side. 
Envarsus 4 mg tablete s produljenim oslobađanjem su ovalne, bijele do bjelkaste neobložene tablete, s utisnutom oznakom „4“ na jednoj strani i „TCS“ na drugoj strani.
Lansoprazol and ciclosporin may potentially inhibit CYP3A4-mediated metabolism of tacrolimus and, thereby, increase tacrolimus whole blood concentrations. 
CYP3A4 i time povećati koncentraciju takrolimusa u punoj krvi.
Make sure that you receive the same tacrolimus medicine every time you collect your prescription, unless your transplant specialist has agreed to change to a different tacrolimus medicine. 
Pazite da Vam pri svakom podizanju lijeka na recept dobijete isti lijek koji sadrži takrolimus,
In all, there appears to be no significant difference in the pattern of adverse events suspected to be causally related to study drug between once daily Envarsus and tacrolimus immediate-release capsules (Prograf). 
Općenito, čini se da između Envarsusa primijenjenog jedanput na dan i kapsula takrolimusa s trenutnim oslobađanjem (Prograf) nema značajne razlike u uzorku štetnih događaja za koje se sumnja da su uzročno povezani s ispitivanim lijekom.
Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including tacrolimus. 
U bolesnika liječenih imunosupresivima, uključujući takrolimus, prijavljeni su slučajevi nefropatije povezane s BK virusom kao i slučajevi progresivne multifokalne leukoencefalopatije
The relationship between tacrolimus trough levels (C24) and systemic exposure (AUC0-24) for Envarsus is similar to that of immediate-release tacrolimus. 
(AUC0-24) za Envarsus sličan je onome za takrolimus s trenutnim oslobađanjem.
Blood and lymphatic system disorders anaemia, thrombocytopenia, leukopenia, red blood cell analyses abnormal, leukocytosis coagulopathies, pancytopenia, neutropenia, coagulation and bleeding analyses, abnormal thrombotic thrombocytopenic purpura, hypoprothrombinaemia, thrombotic microangiopathy pure red cell aplasia, agranulocytosis, haemolytic anaemia 
poremećaj testova koagulacije i krvarenja trombotska trombocito penična purpura, hipoprotrombinemija, trombotska mikroangiopatija izolirana aplazija crvene krvne loze, agranulocitoza,
Each prolonged-release tablet contains 0.75 mg tacrolimus (as monohydrate). 
Jedna tableta s produljenim oslobađanjem sadrži 0,75 mg takrolimusa (tacrolimus) (u obliku hidrata).
fever, nausea or vomiting - an infection, leading to problems with your kidney or neurological symptoms - headache, altered mental status, seizures and visual disturbances - weakness, change in skin or eye colour, easy bruising, infection, cough, anaemia 
- glavobolju, promijenjeno mentalno stanje, napadaje i poremećaje vida - slabost, promjenjenu boju kože ili bjeloočnica, sklonost nastanku modrica, infekciju,
Envarsus 4 mg prolonged-release tablets tacrolimus 
Envarsus 4 mg tablete s produljenim oslobađanjem tacrolimus
CYP3A4 inducers potentially leading to decreased tacrolimus blood levels Clinically, the following substances have been shown to decrease tacrolimus blood levels: Interactions have been observed with rifampicin, phenytoin, and St. John's Wort (Hypericum perforatum) which may require increased tacrolimus doses in almost all patients. 
Primijećene su interakcije s rifampicinom, fenitoinom i gospinom travom (Hypericum perforatum), koje mogu zahtijevati povećanje doze takrolimusa u gotovo svih bolesnika.
Respiratory, thoracic and mediastinal disorders parenchymal lung disorders, dyspnoea, pleural effusion, cough, pharyngitis, nasal congestion and inflammations respiratory failures, respiratory tract disorders, asthma acute respiratory distress syndrome 
dispneja, pleuralni izljev, kašalj, faringitis, nazalna kongestija i upale respiratorno zatajenje,
Envarsus 1 mg prolonged-release tablets tacrolimus 
Envarsus 1 mg tablete s produljenim oslobađanjem tacrolimus
Other interactions potentially leading to increased tacrolimus blood levels Tacrolimus is extensively bound to plasma proteins. 
Druge interakcije koje mogu povećati koncentraciju takrolimusa u krvi
Hepatic impairment 
hipertenziju i nesanicu.
Benign as well as malignant neoplasms including EBV-associated lymphoproliferative disorders and skin malignancies have been reported in association with tacrolimus treatment. 
Prijavljena je povezanost između liječenja takrolimusom te dobroćudnih i zloćudnih neoplazmi, uključujući limfoproliferativne poremećaje povezane s EBV-om i zloćudne promjene na koži.
Package leaflet: Information for the patient Envarsus 0.75 mg prolonged-release tablets Envarsus 1 mg prolonged-release tablets Envarsus 4 mg prolonged-release tablets tacrolimus 
Envarsus 0,75 mg tablete s produljenim oslobađanjem Envarsus 1 mg tablete s produljenim oslobađanjem Envarsus 4 mg tablete s produljenim oslobađanjem takrolimus (tacrolimus)
Dosing should be delayed in the presence of elevated ciclosporin blood levels. 
U slučaju povišenih razina ciklosporina u krvi, doziranje treba odgoditi.
Envarsus 4 mg prolonged-release tablets 
Envarsus 4 mg tablete s produljenim oslobađanjem
This effect may be enhanced if Envarsus is administered in association with alcohol. 
Envarsus uzima zajedno s alkoholom.
Common side effects (may affect up to 1 in 10 people): - reduction in blood cell counts (platelets, red or white blood cells), increase in white blood cell counts, changes in red blood cell counts (seen in blood tests) - reduced magnesium, phosphate, potassium, calcium or sodium in the blood, fluid overload, 
- smanjen broj krvnih stanica (krvnih pločica, crvenih ili bijelih krvnih stanica), povišen broj bijelih krvnih stanica, promjene u broju crvenih krvnih stanica (vidljivo u nalazu pretraga krvi ) - snižena razina magnezija, fosfata, kalija, kalcija ili natrija u krvi, opterećenje tekućinom, povišena razina mokraćne kiseline ili lipida u krvi, smanjen tek, gubitak teka, povišena kiselost krvi, druge promjene u elektrolitima u krvi (vidljivo u nalazu pretraga krvi ) - simptomi tjeskobe, smetenost i gubitak orijentacije, depresija, promjene raspoloženja,
- medicines known as “statins”, used to treat elevated cholesterol and triglycerides - phenytoin or phenobarbital, used to treat epilepsy - prednisolone and methylprednisolone, belonging to the class of corticosteroids and used to treat inflammations or suppress the immune system (e.g. in transplant rejection) - carbamazepine, used to prevent and control seizures - metamizole, used to treat pain and high fever - nefazodone, used to treat depression - herbal preparations containing St. John's Wort (Hypericum perforatum) 
- nilotinib i imatinib (koji se koriste za liječenje određenih vrsta raka) - mikofenolatnu kiselinu, koja se koristi za potiskivanje imunološkog sustava radi sprječavanja odbacivanja presađenog organa - lijekove protiv čira na želucu i povrata želučane kiseline (npr. omeprazol, lanzoprazol ili cimetidin)
Each prolonged-release tablet contains 4 mg tacrolimus (as monohydrate). 
Jedna tableta s produljenim oslobađanjem sadrži 4 mg takrolimusa (tacrolimus) (u obliku hidrata).
Each prolonged-release tablet contains 1 mg tacrolimus (as monohydrate). 
Jedna tableta s produljenim oslobađanjem sadrži 1 mg takrolimusa (tacrolimus) (u obliku hidrata).
Missed dose 
PRIMJENU LIJEKA
Envarsus is a once-a-day oral formulation of tacrolimus. 
Envarsus je peroralni farmaceutski oblik takrolimusa koji se primjenjuje jedanput na dan.
Envarsus 1 mg prolonged-release tablets 
Envarsus 1 mg tablete s produljenim oslobađanjem
Envarsus contains lactose. 
Pomoćne tvari Envarsus sadrži laktozu.
Each prolonged-release tablet contains 4.0 mg tacrolimus (as monohydrate). 
Jedna tableta s produljenim oslobađanjem sadrži 4,0 mg takrolimusa (u obliku hidrata).
Prophylaxis of kidney transplant rejection 
Sprječavanje odbacivanja presatka bubrega
Each prolonged-release tablet contains 1.0 mg tacrolimus (as monohydrate). 
Jedna tableta s produljenim oslobađanjem sadrži 1,0 mg takrolimusa (u obliku hidrata).
hallucination, mental disorders - fits, disturbances in consciousness, tingling and numbness (sometimes painful) in the hands and feet, dizziness, impaired writing ability, nervous system disorders - blurred vision, increased sensitivity to light, eye disorders - ringing sound in your ears - reduced blood flow in the heart vessels, faster heartbeat - bleeding, partial or complete blocking of blood vessels, reduced blood pressure - shortness in breath, disorders of the respiratory tissues in the lung, collection of liquid around the lung, inflammation of the pharynx, cough, flu-like symptoms - stomach problems such as inflammation or ulcer causing abdominal pain or diarrhoea, bleeding in the stomach, inflammation or ulcer in the mouth, collection of fluid in the belly, vomiting, 
- krvarenje, djelomično ili potpuno začepljenje krvnih žila, snižen krvni tlak, - nedostatak zraka, promjene u plućnom tkivu, nakupljanje tekućine oko pluća, upala ždrijela, kašalj, simptomi nalik gripi - problemi sa želucem poput upale ili ulkusa koji izazivaju bol u trbuhu ili proljev,
Very rare side effects (may affect up to 1 in 10,000 people): - Muscular weakness - Impaired hearing - Abnormal heart scan - Liver failure - Painful urination with blood in the urine - Increase of fat tissue 
- žeđ, pad, osjećaj stezanja u prsištu, smanjena pokretljivost, ulkus Vrlo rijetke nuspojave (mogu se pojaviti u do 1 na 10 000 osoba): - slabost mišića - oštećenje sluha
When converting from tacrolimus immediate-release products (e.g. Prograf capsules) or from Advagraf prolonged-release capsules to Envarsus, trough levels should be measured prior to conversion and within two weeks after conversion. 
Advagrafa s produljenim oslobađanjem na Envarsus, moraju se odrediti najniže koncentracije takrolimusa prije prelaska te unutar 2 tjedna nakon prelaska.
Blood trough levels of tacrolimus should be monitored during the post-transplantation period. 
Tijekom razdoblja nakon presađivanja organa potrebno je pratiti najniže razine takrolimusa u krvi.
abdominal pain, indigestion, constipation, passing wind, bloating, loose stools - bile duct disorders, yellowing of the skin due to liver problems, liver tissue damage and inflammation of the liver - itching, rash, hair loss, acne, increased sweating - pain in joints, limbs or back, muscle cramps - insufficient function of the kidneys, reduced production of urine, impaired or painful urination - general weakness, fever, collection of fluid in your body, pain and discomfort, increase of the enzyme alkaline phosphatase in your blood, weight gain, feeling of temperature disturbed - insufficient function of your transplanted organ 
- poteškoće s disanjem, poremećaji dišnog sustava, astma - akutna ili kronična upala gušterače, upala sluznice koja oblaže unutarnju stijenku trbušne šupljine, začepljenje crijeva, povišena razina enzima amilaze u krvi, vraćanje sadržaja želuca u grlo, usporeno pražnjenje želuca
Gastrointestinal disorders diarrhoea, nausea gastrointestinal signs and symptoms, vomiting, gastrointestinal and abdominal pains, gastrointestinal inflammatory conditions, gastrointestinal haemorrhages, gastrointestinal ulceration and perforation, ascites, stomatitis and ulceration, constipation, dyspeptic signs and symptoms, flatulence, bloating and distension, loose stools acute and chronic pancreatitis, peritonitis, ileus paralytic, gastrooesophageal reflux disease, impaired gastric emptying pancreatic pseudocyst, subileus 
gastrointestinalni i abdominalni bolovi, upalna stanja probavnog sustava, krvarenje u probavnom sustavu, ulceracije i perforacije probavnog sustava, ascites, stomatitis i ulceracije, konstipacija,
Vascular disorders hypertension thromboembolic and ischaemic events, vascular hypotensive disorders, haemorrhage, peripheral vascular disorders venous thrombosis deep limb, shock, infarction 
poremećaji perifernih krvnih žila duboka venska tromboza udova, šok, infarkt
Therapeutic drug monitoring of mycophenolic acid may be appropriate when switching from ciclosporin to tacrolimus or vice versa. 
Pri prelasku s ciklosporina na takrolimus i obrnuto možda će biti potrebno terapijsko praćenje koncentracija mikofenolatne kiseline.
While you take Envarsus your doctor also needs to know if you are taking potassium supplements or certain diuretics used for heart failure, hypertension and kidney disease (e.g. amiloride, triamterene, or spironolactone), nonsteroidal anti-inflammatory substances (NSAIDs, e.g. ibuprofen) used for fever, inflammation and pain, anticoagulants (blood thinners), or oral medicines for diabetes. 
nesteroidne protuupalne lijekove (NSAIL, npr. ibuprofen) koji se koriste protiv vrućice, upale i bolova; antikoagulanse (za razrjeđivanje krvi), ili oralne lijekove za liječenje šećerne bolesti.
Very common side effects (may affect more than 1 in 10 people): - increased blood sugar, diabetes mellitus, increased potassium in the blood - difficulty in sleeping - trembling, headache - increased blood pressure - liver function tests abnormal - diarrhoea, nausea - kidney problems 
- povišen šećer u krvi, šećerna bolest, povišena razina kalija u krvi - poteškoće sa spavanjem
Therapeutic drug monitoring 
FARMACEUTSKI PODACI
Hypromellose 
hemolitička anemija
The educational material for Healthcare Professionals should include information on the following key elements: - The authorised indications - The need for prescribing and dispensing with attention to pharmaceutical form (prolonged-release) and posology (once daily administration). 
- Odobrene indikacije - Potrebu da se prilikom propisivanja i izdavanja lijeka obrati pažnja na farmaceutski oblik